With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

Eli Lilly is partnering on Team USA’s push to help Olympic and Paralympic athletes hurdle the challenges of recovering from ...

In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce ...

The new audio show builds on recent efforts by AbbVie to boost awareness of its teams’ patient-driven work, including in the “I Am” corporate campaign that launched last summer and spotlights both ...

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai ...

President Donald Trump has found himself in an odd juxtaposition as traditional allies are pushing back on his Most Favored Nation (MFN) plan to reduce the price of prescription drugs.  < | As ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

In a statement, EyePoint CEO Jay Duker, M.D., lauded Campbell’s “proven track record of successfully launching innovative ...

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

In the seven-plus years since Bayer closed its mammoth buyout of Monsanto, the combined company has struggled to contain litigation surrounding the crop sciences firm's ubiquitous weedkiller Roundu | ...